[I do not remember this but decision could be this week.]
Can BioXCel Push Psychiatric Disorder-Associated Agitation Drug Past Finish Line?
- Company: BioXcel Therapeutics, Inc. (NASDAQ: BTAI)
- Type of Application: new drug application
- Candidate: dexmedetomidine (BXCL501)
- Indication: agitation associated with schizophrenia and bipolar disorders I and II.
- Date: April 5
BXCL501 is an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation associated with neuropsychiatric disorders. The original PDUFA date of Jan. 5, 2022 was pushed back by three months, with BoXcel communicating that the FDA needed three more months to review data.